Both PD-1 and PD-L1 blockade elicited a potent NK cell response as well [41].The US Food and Drug Administration (FDA) approved anti-PD-1 therapy has become a promising immunotherapy strategy for HCC. The gene discussed is CD274; the disease is hepatocellular carcinoma.